Microba Life Sciences : International Conference Presentation

ASX Announcement 29 April 2022

Microba to Present at International Microbiome Conference

For personal use only

Dr Luke Reid	Simon Hinsley
Chief Executive Officer	Investor / Media Relations
E:[e-mail]	E:[e-mail]
T: [phone]
About Microba Life Sciences Limited

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to announce Global Business Development lead, Mark Parker, will present at the 3rd International World of Microbiome Conference in Vienna on Saturday 30 April from 10:20AM CET (6:20PM AEST). Microba is continuing to attract new business opportunities in Europe through an increased presence following the COVID period. A copy of the presentation is attached to this announcement.

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit:www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

Microba Life Sciences Ltd ABN 82 617 096 652

Level 10, 324 Queen Street, Brisbane QLD 4000 Australia

T: 1300 974 621 E:[e-mail] W:microba.com

Microba's Discovery Platform

A unique dataset for discovery

World of Microbiome | Vienna

Mark Parker

Global Business Development, Microba Life Sciences

April 2022 | Authorised for release by the CEO and Chairman

There is unequivocal evidence demonstrating the human gut microbiome acts systemically and is a critical factor in disease

Deficient analysis and fragmented datasets are limiting progress

• • Incomplete measurement of gut microbiome communities

• • High error rates with existing tools

• • Underpowered datasets leading to unclear results

• • Resistance to culture impedes efforts to assess therapeutic efficacy of priority microbes

Microba's data-driven discovery interrogates the novel microbiome

Precision techniques developed by Microba enable access to greater depth and breath of the microbiome with precision and efficiency.

*Almeida et al (2020) DOI:10.1038/s41587-020-0603-3

Microba's leading metagenomics analysis platform measures the microbiome with unparalleled performance

Microba Community ProfilerMicroba

Genome Database

Metagenomic mapping technology delivering leading microbiome measurement when combined with Microba's Genome Database

World leading, expertly curated microbial genome reference database of microbial genomes to deliver unmatched detection coverage of the human microbiome

Data generated by Microba Life Sciences

1 Parks et al 2021 DOI:10.3389/fmicb.2021.643682